Brief: Vanda Pharmaceuticals And OliPass Announce Strategic Partnership To Develop Antisense Oligonucleotide Therapeutics
29/09/2022 21:30
Sept 29 (Reuters) - OliPass Corp 244460.KQ :
* VANDA PHARMACEUTICALS AND OLIPASS ANNOUNCE STRATEGIC
PARTNERSHIP
TO DEVELOP ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS
Source text for Eikon: ID:nPnk02dRa
Further company coverage: 244460.KQ
Recent news on OliPass
See all newsBrief: Olipass To Acquire Real Estate Worth 72 Billion Won
Brief: Olipass To Conduct Capital Increase Of 6.5 Billion Won
Brief: Olipass To Conduct Capital Increase Of 5 Billion Won For Operational Funds
Brief: Vanda Pharmaceuticals And OliPass Announce Strategic Partnership To Develop Antisense Oligonucleotide Therapeutics
Brief: Olipass Corp SCN9A Antisense Pain Killer OLP-1002 Moves Into Phase 2A Stage